With EU CE mark clearance for LigaSure RAS, Medtronic expands the Hugo system’s capabilities in gynaecologic and urologic ...

Medtronic said its market-leading LigaSure technology can now be used with its Hugo soft tissue robotic surgery system in ...

Medtronic announced today that it received CE mark for its LigaSure vessel sealing technology for use with its Hugo system.

Medtronic has announced the first subject enrolment in the Peripheral Onyx Liquid Embolic (PELE) trial. The study aims to ...

Medtronic's long-term dividend streak also points to a business capable of performing well over long periods. Healthcare ...

Medtronic's Jason Fontana offers an update on next-generation Symplicity Spyral devices, procedures and a new feature they're ...

Medtronic is a diversified medical device company with a low-growth value stock position. The Hugo RAS system has the potential to drive significant growth for Medtronic in the robotic-assisted ...

Medtronic has filed for Food and Drug Administration approval of its Hugo soft tissue robotic surgery system with a urologic indication, marking a major step in its bid to compete with Intuitive ...

Medtronic has enrolled the first patient in a U.S. clinical trial of its Hugo robotic-assisted surgery system, advancing its push to challenge Intuitive Surgical.

That makes Medtronic a top stock for income seekers, and the recent Hugo-related developments only make it more attractive. Should you invest $1,000 in Medtronic right now?

Medtronic also announced today that it submitted the Hugo RAS system to the U.S. Food and Drug Administration (FDA) for a urologic indication in the first quarter of calendar 2025.